title: Pediatric vitiligo.
abstract: Vitiligo is a disease of pigment loss. Most investigators currently consider vitiligo to be a disorder that occurs as a result of autoimmune destruction of melanocytes, supported by identification of antimelanocyte antibodies in many patients, and the presence of comorbid autoimmune disease in patients with and family members of individuals with vitiligo. One-half of vitiligo cases are of childhood onset. This article presents a current overview of pediatric vitiligo including comorbidities of general health, psychological factors, therapeutic options, and long-term health considerations.
authors.affiliation: Department of Dermatology, St. Luke's-Roosevelt Hospital Center, Icahn School of Medicine at Mount Sinai, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA. Electronic address: nsilverb@chpnet.org.
authors.forename: Nanette B
authors.initials: NB
authors.lastname: Silverberg
mesh_terms: D001327:Autoimmune Diseases / Q000150:complications*; D002648:Child; D015897:Comorbidity; D003937:Diagnosis, Differential; D006801:Humans; D014820:Vitiligo / Q000150:complications* / Q000175:diagnosis / Q000628:therapy
keywords: Autoimmunity; Corticosteroids; Depigmentation; Tacrolimus; Vitamin D; Vitiligo